TABLE 1.
Demographic, clinical, and laboratory data for 104 liver transplant recipients with therapeutic drug monitoring of voriconazole
| Variable | Value |
|---|---|
| Mean (range) age (yr) | 36 (18–62) |
| Sex (no. [%] of males, no. [%] of females) | 60 (58), 44 (42) |
| Mean (range) wt (kg) | 61 (34–90) |
| No. (%) of patients with invasive fungal infection | |
| Proven | 8 (7.7) |
| Probable | 42 (40.4) |
| Possible | 54 (51.9) |
| No. (%) of patients with route of administration | |
| Intravenous | 24 (23) |
| Oral | 80 (77) |
| No. (%) of patients with CYP2C19 genotypea | |
| Homozygous extensive metabolizer | 30 (40) |
| Heterozygous extensive metabolizer | 24 (32) |
| Poor metabolizer | 7 (9.3) |
| Ultrarapid metabolizer | 14 (18.7) |
| Mean (range) duration of therapy (days) | 54 (29–98) |
| Median (range) duration of voriconazole therapy posttransplantation (days)b | 39 (21–50) |
| Median (range) voriconazole daily dose (mg/kg/day) | |
| Intravenous | 8.0 (6–10) |
| Oral | 7.35 (4–9.4) |
| Median (range) voriconazole trough level (μg/ml) | 2.49 (0–11.86) |
a
Genotypes were evaluated by use of allograft liver biopsy specimens from 75 liver transplant recipients (72% of patients).
b
Median time interval between liver transplantation and the first voriconazole trough level measurement.